ClinicalTrials.Veeva

Menu

The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study (DOCTOR Recross)

A

Aarhus University Hospital Skejby

Status

Unknown

Conditions

Coronary Disease

Treatments

Procedure: OCT
Procedure: Angiography
Device: Xience Prime Stent
Device: Medtronic Resolute Integrity stent

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT02234804
1-10-72-111-13

Details and patient eligibility

About

Prospective, controlled, double randomized, non-blinded, multicenter, investigator initiated, academic superiority trial comparing optical coherence tomography (OCT) guided vs. angiography guided wire recrossing in jailed side branches (SB) (1. randomization 1:1)(superiority) and comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium (2. randomization 1:1) (superiority). Acute primary endpoint and 30 days clinical follow-up.

Hypothesis: OCT guided wire recrossing in bifurcation stenting results in less malapposed struts in the segment facing the SB ostium.

Secondary hypothesis: Treatment by Medtronic Resolute Integrity stent results in less malapposed struts at the bifurcation segment compared to treatment by the Abbott Xience Prime stent.

Full description

Purpose:

To assess the ability of OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.

To compare stent strut apposition after treatment by two different stent designs using both guiding strategies of wire recrossing.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stable or unstable angina pectoris or silent angina pectoris.
  • De novo coronary bifurcation lesions at "LAD/diagonal", "Cx/obtuse marginal", "right coronary artery (RCA)- posterior descending artery (PDA)/posterolateral branch" or "left main (LM)/Cx/LAD".
  • All Medina classes except Medina 0.0.1.
  • Diameter of side branch ≥2.5 mm.
  • Diameter stenosis >50% by operator's visual assessment
  • Signed informed consent

Exclusion criteria

  • ST-elevation infarction within 48 hours.
  • Side branch lesion length >5 mm.
  • Expected survival < 1 year
  • Severe heart failure (NYHA≥III)
  • S-creatinine >120 µmol/l.
  • Allergy to Contrast media, Aspirin, Clopidogrel, Ticagrelor, Ticlopidine, Everolimus or Zotarolimus.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 4 patient groups

Medtronic Resolute Integrity stent
Experimental group
Description:
Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
Treatment:
Procedure: Angiography
Procedure: OCT
OCT
Experimental group
Description:
OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
Treatment:
Device: Medtronic Resolute Integrity stent
Device: Xience Prime Stent
Angiography
Active Comparator group
Description:
Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
Treatment:
Device: Medtronic Resolute Integrity stent
Device: Xience Prime Stent
Xience Prime stent
Active Comparator group
Description:
Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
Treatment:
Procedure: Angiography
Procedure: OCT

Trial contacts and locations

3

Loading...

Central trial contact

Evald H Christiansen, MD; Niels R Holm, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems